CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
April 22, 2020
 CRC9 (NCT04068103), Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA), has been centrally activated. Read More |
COVID-19 Update: CCTG guidance documents and updated FAQPublished: April 22, 2020Category: Group updates  CCTG has developed guidance documents to facilitate continuing patients on trials or how to modify (and document) protocol requirements for individual patient management as needed. Please note that an updated Frequently Asked Questions (FAQs) document has been posted to the CCTG COVID-19 members webpage. Also new are posted links to the previously communicated important memos dated 2020MAR17, 2020MAR27 and 2020APR06. Read More |
 A guest editorial first published in the "Cancer Letter"
While the National Clinical Trials Network (NCTN) groups remain open for business during the pandemic, it’s not business as usual. For good reason, clinical trials are taking a backseat to clinical care. Leadership and members themselves face significant challenges treating oncology patients, as attention and resources are diverted to minister to those with COVID-19. Read More |
 CCTG has been made aware of an opportunity that may be of interest to our member centres during this COVID-19 pandemic. Jonathan Loree and colleagues at BC Cancer have developed a protocol to help Canadian centres track outcomes among patients with cancer who develop COVID-19. Read More |
 IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodriguez, Tanya Skamene, Lawrence Panasci, Bingshu E. Chen & Annette E. Hay Read More |
April 08, 2020
 The CCTG BR31 (NCT02273375) trial, A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer has been closed to accrual to the main study. The purpose of this study was to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer. Read More |
 This past week the central office has continued to support CCTG network activities including addressing impacts of COVID-19. CCTG regulatory/ethics compliance and trial teams rolled out COVID-19 addenda for all trials. These addenda have been added to all CCTG trial pages to support sites and trial teams in our network. We are also incorporating an EDC form for the collection of COVID-19 information for designated trials. Read More |